U.S. Markets closed

How These Gene Therapy Stocks Benefit From Novartis-AveXis Deal

ALLISON GATLIN
How These Gene Therapy Stocks Benefit From Novartis-AveXis Deal

Audentes, Spark and uniQure popped Tuesday after Novartis' $8.7 billion plan to buy AveXis put a spotlight on other gene therapy players.